Inhibition of Th17 Cell Differentiation as a Treatment for Multiple Sclerosis

Abstract

The goal of this project is to develop miR-326 small molecule inhibitors (SMIs) for the treatment of Multiple Sclerosis (MS). Our global approach consists of creating stable transfectants with a luciferase reporter gene and 3 target sequence for miR-326. The addition of hsa-miR-326 (delivered either by lentivirus or cotransfection) should result in reduced fluorescence and the addition of putative inhibitors will restore the luciferase-dependent fluorescence. A great deal of time on this project has been devoted to troubleshooting unforeseen problems with transfection and establishing stable cell lines expressing constructs of interest. During the supported period we successfully generated plasmids to be used for stable and transient transfections of miR-326 and miR-21 (as control miRNA).

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2012
Accession Number
ADA577274

Entities

People

  • Annalisa D'andrea

Organizations

  • SRI International

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Coding
  • Diseases And Disorders
  • Fluorescence
  • Inhibitors
  • Luminescence
  • Molecules
  • Multiple Sclerosis
  • Sclerosis
  • Sequences
  • Small Molecules
  • Transfection
  • Tumor Cell Line

Readers

  • Medical Imaging.
  • Molecular Genetics